

Therapeutic monoclonal antibodies used for Multiple Myeloma – Interference Problems with SPE and Immunofixation

Effective Date: 05/01/2018

Because therapeutic monoclonal antibodies recently introduced for the treatment of multiple myeloma are human monoclonal antibodies, they may cause problems with interpretation of serum immunofixation and serum protein electrophoresis.

Both Darzalex (Daratumumab) and Empliciti (Elotuzumab) are IgG kappa monoclonal antibodies; however, IgG lambda monoclonals are also in development. If these are at high enough serum concentrations, they will appear as an IgG kappa or IgG lambda monoclonal protein on routine testing.

Therefore, if any patient is receiving a therapeutic monoclonal antibody, it is strongly recommended that blood be obtained for serum immunofixation or serum protein electrophoresis testing just before the patient receives the next drug dose (i.e. “trough”).

If you have questions, please contact Client Services (1-800-551-0488, option 5).

Laboratory Test Directory: <http://beaumontlaboratory.com/test-lab-directory>.

Date submitted: April 24, 2018

Submitted By: Elizabeth Sykes, M.D., Medical Director, Automated Chemistry and Special Testing, Clinical Pathology

Yvonne Posey, M.D., Associate Medical Director, Automated Chemistry & Special Testing

Beaumont Laboratory
Customer Service
1-800-551-0488